bluebird buys Seattle-based biotech


bluebird bio (BLUE -2.1%) acquires privately-held Precision Genome Engineering (Pregenen) in an all-stock deal. Pregenen stakeholders receive 408,667 BLUE shares but can earn up to $15M in cash based on achieving certain preclinical milestones, up to $20.1M in cash for achieving certain clinical milestones and up to $99.9M in cash for achieving certain commercial milestones. BLUE also assumes $4.9M in debt.

Progenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs